Table 8.
A review of the literature concerning HPV prevalence in Polish patients with squamous cell carcinoma of head and neck
| Authors | No. of specimens | Tumour site | Method/kit used for HPV detection | HPV prevalence [%] | Genotypes detecteda | Active infection assessed (yes/no) |
|---|---|---|---|---|---|---|
| Szkaradkiewicz et al. (2002) | 28 | Oropharynx | PCR-ELISA | 10.7 | – | No |
| Morshed (2010) | 130 | Larynx | Immunohistochemistry | 27.7 | – | No |
| 93 | SPF-10 PCR and DNA enzyme immunoassay | 35.5 | ||||
| Polz et al. (2010) | 60 | Oral cavity oropharynx | INNO-LiPA HPV genotyping CE amp kit | 25.0 |
HPV16 (87%) not identified types (13%) |
No |
| Snietura et al. (2011) | 66 | Oral cavity/ oropharynx | Real time high risk HPV test for detection of 14 HPV types | 6.9 (13.6% within oral cavity/ oropharynx and 0% within larynx) | HPV16 (100%) | No |
| 65 | Larynx | |||||
| Golusinski et al. (2012) | 50 | Oral cavity oropharynx larynx | p16 immunostaining and GP5 + /6 + PCR, followed by RLB hybridization | 0.0 | none | Yes |
| Józefowicz-Korczyńska et al. (2014) | 100 | Larynx | INNO-LiPA HPV genotyping extra assay | 23.0 |
HPV18 (30%) HPV16 (22%) not identified types (48%) |
No |
| Polz-Gruszka D. et al. (2015) | 50 | Larynx |
INNO-LiPA HPV genotyping extra assay |
32.5 (26.7% within oropharynx and 36.0% within larynx) |
HPV16 (69%) HPV45, 59 and 68 (31%) |
No |
| 30 | Oropharynx | |||||
| Mazurek et al. (2016) | 63 | Oropharynx | qPCR (assessment of HPV16 DNA in plasma and tumour samples) |
38.0 in plasma samples 57.0 in tumour samples |
only HPV16 was identifying | No |
| Prawdzic Seńkowska et al. (2019) | 47 | Oral cavity |
GenoFlow HPV array test kit for detection of 33 HPV types |
31.9 |
HPV16 (47%) HPV 18 (7%) HPV 43/44 (40%) |
No |
aIn brackets percentages per all detected HPV positive cases are presented